China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic biology-driven platforms for engineered macrophages to treat solid tumors, has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by ASB Ventures, Riemann Hypothesis, and other investors. The proceeds will be used to support laboratory platform construction, pipeline development and pre-clinical studies, patent layout, and company operations.
Company Background and Technology Platforms
Founded in 2021, Kunshi Biotechnology is known for its innovative 24-hour ready chimeric antigen receptor macrophages (CAR-M) preparation technology platform, “24H-CAR.” The company also features an enhanced synthesis platform, “ADM-CAR,” based on iterative screening of macrophage activation domains, a macrophage-based macromolecule delivery platform, “Del-M,” and a subtype database and target database platform, “M-DB.” These platforms collectively serve as a robust source of innovation for CAR-M therapies targeting various solid tumors.
Future Outlook
The angel financing round underscores Kunshi Biotechnology’s commitment to advancing its engineered macrophage platforms. By leveraging the funds, the company aims to enhance its laboratory capabilities, develop its pipeline, and conduct pre-clinical studies, positioning itself at the forefront of gene editing and synthetic biology in oncology.-Fineline Info & Tech
